SPL026 With or Without SSRIs in Participants With MDD

Summary

The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine \[DMT\] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.

Timeline

Start

2022-12-13

Primary completion

2023-08-03

Completion

2023-08-03

Publications

• Hagel JM, Chang L, Li J, Chen X, Yu L, Gallant JA, Facchini PJ. Bioproduction of a Large-Scale Library of Tryptamine Derivatives for Neuropsychiatric Drug Screening. ACS Chem Biol. 2025 Jun 20;20(6):1212-1231. doi: 10.1021/acschembio.4c00857. Epub 2025 May 15.

Drugs

Indications